OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher HealthcareGlobeNewsWire • 04/18/23
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection PanelGlobeNewsWire • 04/18/23
OpGen's Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnosticsGlobeNewsWire • 04/03/23
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/23
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/29/23
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern TimeGlobeNewsWire • 03/22/23
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business GrowthGlobeNewsWire • 03/01/23
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration ProjectGlobeNewsWire • 01/17/23
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection PanelGlobeNewsWire • 12/13/22
OpGen Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/22
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business UpdateGlobeNewsWire • 10/27/22
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard TimeGlobeNewsWire • 10/27/22
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial SupportGlobeNewsWire • 10/25/22